PRKG1 and metachromatic leukodystrophy: The PGK promoter has now been used in the context of self-inactivating LV vectors in a clinical trial of HSC gene therapy for metachromatic leukodystrophy with considerable efficacy26 and may have advantages for other hematopoietic diseases.